Virus cocktail takes on superbugs in cystic fibrosis trial
NCT ID NCT07280598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether adding specially-made viruses (phages) to standard antibiotics can safely treat stubborn lung infections in adults with cystic fibrosis. About 30 participants will receive a 7-day course of both treatments. The main goal is to check safety, but researchers will also measure changes in bacteria levels and lung function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHROMOBACTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer patients may need higher antibiotic doses to beat superbugs
- Tracking immune recovery after sepsis: clues to better outcomes
- Tiny bacterial particles linked to lung damage in sepsis patients
- Scientists crack the code of antibiotic-friendly superbug
- New hope for lung infection sufferers: inhaled antibiotic trial shows promise
- Virus cocktail targets superbug pneumonia in first human test